Arcellx, Inc. (ACLX)
NASDAQ: ACLX · Real-Time Price · USD
62.81
-5.15 (-7.58%)
Mar 31, 2025, 9:47 AM EDT - Market open

Company Description

Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States.

The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).

It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; ARC-SparX programs in Phase 1 trials; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).

In addition, the company preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, the company focuses on the development of product candidates for solid tumor programs.

It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel.

The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016.

Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

Arcellx, Inc.
Arcellx logo
Country United States
Founded 2015
IPO Date Feb 4, 2022
Industry Biotechnology
Sector Healthcare
Employees 163
CEO Rami Elghandour

Contact Details

Address:
800 Bridge Parkway
Redwood City, California 94065
United States
Phone 240 327 0630
Website arcellx.com

Stock Details

Ticker Symbol ACLX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
IPO Price $15.00
CIK Code 0001786205
CUSIP Number 03940C100
ISIN Number US03940C1009
Employer ID 47-2855917
SIC Code 2836

Key Executives

Name Position
Rami Elghandour Chairman of the Board, Chief Executive Officer and President
Michelle Lim Gilson Chief Financial Officer
Dr. Christopher R. Heery M.D. Chief Medical Officer
Narinderjeet Singh M.S. Chief Technical Officer
Dr. Heba Nowyhed Ph.D. Chief Scientific Officer
Myesha Lacy Chief Investor and Communications Officer
Maryam Abdul-Kareem J.D., M.S. General Counsel and Chief Legal Officer
Kate Aiken Chief People Officer
Neeraj P. Teotia Chief Commercial Officer
Aileen Fernandes Chief Business Officer

Latest SEC Filings

Date Type Title
Mar 20, 2025 8-K Current Report
Feb 27, 2025 8-K Current Report
Feb 27, 2025 10-K Annual Report
Feb 27, 2025 SCHEDULE 13D/A Filing
Feb 26, 2025 144 Filing
Feb 25, 2025 144 Filing
Feb 24, 2025 144 Filing
Feb 12, 2025 SCHEDULE 13G/A Filing
Jan 30, 2025 SCHEDULE 13G Filing
Jan 7, 2025 144 Filing